arrow
S

Sara Delfanti

Azienda Ospedaliera Universitaria
H指数:16
被引数:726

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Tumor DNA methylation subtypes predict immunotherapy outcomes in pleural mesothelioma patients in the NIBIT-EPI-MESO study

NIBIT-epi-meso研究中肿瘤DNA甲基化亚型预测胸膜间皮瘤患者的免疫治疗结果

2026-04-270
PRE
Durable complete response in a patient with BRAF-mutated advanced melanoma with ocular and skin toxicities from BRAF/MEK targeted therapy after checkpoint inhibitor treatment: a case report

BRAF突变晚期黑色素瘤患者在接受免疫检查点抑制剂治疗后出现眼部和皮肤毒性的BRAF/MEK靶向治疗,并获得持久完全缓解:病例报告

2026-01-010
OA
Methylation subtypes correlate with tumor immune contextures and outcome to ICI therapy of pleural mesothelioma (PM) patients: The NIBIT EPI-MESO study

甲基化亚型与胸膜间皮瘤(PM)患者肿瘤免疫微环境和ICI疗法结局的相关性:NIBIT EPI-MESO研究

2024-09-010
PRE
Mytomicin-C, Metronomic Capecitabine, and Bevacizumab in Patients With Unresectable or Relapsed Pseudomyxoma Peritonei of Appendiceal Origin
2023-12-013
PRE
Pembrolizumab plus chemotherapy versus chemotherapy in untreated advanced pleural mesothelioma in Canada, Italy, and France: a phase 3, open-label, randomised controlled trial
LANCET
IF88.5
2023-12-0113
PRE
Vaccination against SARS-CoV-2 protects from morbidity, mortality and sequelae from COVID19 in patients with cancer

接种SARS-CoV-2疫苗可预防癌症患者COVID19的发病率、死亡率和后遗症

2022-08-0123
OAAI
Pilot Study to Evaluate Serum Soluble Mesothelin-Related Peptide (SMRP) as Marker for Clinical Monitoring of Pleural Mesothelioma (PM): Correlation with Modified RECIST Score
2021-10-294
OAAI
Early intravenous administration of nutritional support (IVANS) in metastatic gastric cancer patients at nutritional risk, undergoing first-line chemotherapy: study protocol of a pragmatic, randomized, multicenter, clinical trial
2020-02-227
OAAI
Phase II randomised study of maintenance treatment with bevacizumab or bevacizumab plus metronomic chemotherapy after first-line induction with FOLFOXIRI plus Bevacizumab for metastatic colorectal cancer patients: the MOMA trial
2019-03-0127
PREAI
In Vitro Killing of Colorectal Carcinoma Cells by Autologous Activated NK Cells is Boosted by Anti-Epidermal Growth Factor Receptor-induced ADCC Regardless of RAS Mutation Status

抗表皮生长因子受体诱导的ADCC增强了自体活化的NK细胞对结直肠癌细胞的体外杀伤,而与RAS突变状态无关

2018-05-0125
PREAI
FOLFOXIRI plus bevacizumab (bev) followed by maintenance with bev alone or bev plus metronomic chemotherapy (metroCT) in metastatic colorectal cancer (mCRC): The phase II randomized MOMA trial
2016-10-014
OAAI